ABSTRACT-We examined whether opening of the ATP-sensitive potassium (KATP) channels in the ischemic myocardium plays an important cardioprotective role during ischemia. Dogs were anesthetized with sodium pentobarbital (30 mg/kg, i.v.). Sixty minutes after treatment of the dog with glibenclamide (0.3 or 3 mg/kg, i.v.), the LAD was ligated. At 3 or 15 min after LAD ligation, left ventricular tissue was taken from the ischemic region to measure tissue metabolite levels. After ischemia, the tissue levels of ATP and creatine phosphate decreased to 49-7401o and 26-34%, respectively, and lactate level increased to 380-660%. Ischemia (either 3 or 15 min) increased the levels of G6P and F6P and decreased the FDP level, indicating the inhibition of glycolysis. Glibenclamide at either dose decreased the level of blood glucose by 20-3007o and increased the blood insulin level twice. The decrease in ATP and increase in lactate due to ischemia were significantly enhanced by glibenclamide at a dose of 3 mg/kg. The increase in G6P due to 15 min of ischemia were also enhanced significantly by 0.3 and 3 mg/kg of glibenclamide. Glibenclamide worsened the metabolic alterations produced by ischemia. These results suggest that KATP channels that can be inhibited by glibenclamide may perform some functions in the ischemic myocardium.
By the use of a patch clamp method, ATP-sensitive potassium (KATP) channels were found first in the myo cardial cell (1) , and then in the pancreatic (3 cell (2) . The cells of other organs also possess KATP channels (3 5) . This channel plays a role in shortening of the action poten tial in the myocardium (6) , insulin secretion in the pan creas (7) and vasodilation in vascular smooth muscle (8) . Sulfonylureas, oral hypoglycemic agents, inhibit KATP channel in the cell membrane of the pancreatic i cells. This effect leads to depolarization of the cell membrane, which in turn increases Ca 21 influx through voltage-sensi tive Ca2+ channels, and thus triggers insulin release (7) . Glibenclamide, an antidiabetic sulfonylurea, is a specific KATP channel antagonist, which is widely used for the ex periments on KATP channels.
In the heart, ischemia opens KATP channels in the myo cardial cells because it reduces the ATP level (9, 10) . Opening KATP channels decreases the cytoplasmic Ca ion concentration because of inhibition of Ca 21 influx through voltage-sensitive Ca 21 channels (11) . This results in a decrease in cardiac contractile force. Although there is no evidence that the ATP level in the coronary arteries decreases during ischemia, in vitro experiments reveal that the increase in blood flow produced by ischemia is possibly mediated by KATP channels (12) . The cardio depression and coronary dilation caused by opening of the KATP channels improve oxygen supply-demand im balance. During ischemia, KATP channels may be involved in the mechanism by which myocardial ischemic damage is lessened. If this is true, blockade of KATP channels would enhance the ischemic injury. The present study, therefore, was undertaken to examine the effect of gliben clamide on changes in the myocardial energy and carbohy drate metabolism during ischemia.
MATERIALS AND METHODS
The investigation conforms with the Guiding Principles for the Care and Use of Laboratory Animals approved by
The Japanese Pharmacological Society.
Animal preparation Healthy mongrel dogs (68 animals) of either sex weigh ing 7 26 kg were used under pentobarbital (30 mg/kg, i.v.) anesthesia. Animals were endotracheally intubated and ventilated with a respirator. A left thoracotomy was performed between the fourth and fifth ribs to expose the left ventricular wall. After suspending the heart in a pericardial cradle, the main trunk of the left anterior descending coronary artery (LAD) was dissected free from the adjacent tissue and was then loosely encircled with a silk thread for ligation. Ischemia was produced by tightening this thread. Aortic blood pressures were meas ured via cannula introduced from the left femoral artery to near the aortic arch. Heart rate was counted from the QRS signals from an ECG taken in the standard limb lead II. Double products were calculated from the systolic blood pressure and heart rate. Coronary blood flow was measured by an electromagnetic flow probe positioned just proximally to the ligature.
After control observations had been completed, either the vehicle (dimethyl sulfoxide, DMSO) or 0.3 or 3 mg/kg of glibenclamide dissolved with DMSO was injected i.v. over a period of 30 sec into the left femoral vein. Then 60 min later, the ligature around the LAD was not tied (nonischemia) or tied for 3 or 15 min (ischemia). The animals used were divided into the following groups: vehicle-treated nonischemic group (n = 7), 0.3 mg/kg of glibenclamide-treated nonischemic group (n = 6), 3 mg/kg of glibenclamide-treated nonischemic group (n = 9), vehicle-treated 3-min ischemic group (9), 3 mg/kg of glibenclamide-treated 3-min ischemic group (n=9), vehicle-treated 15-min ischemic group (n = 11), 0.3 mg/kg of glibenclamide-treated 15-min ischemic group (n=6), and 3 mg/kg of glibenclamide-treated 15-min ischemic group (n=11). After 3 or 15 min of ischemia, a full thick ness sample of the myocardium (about 10 mm) was taken from the center of the ischemic area identified by the cyanotic appearance. A corresponding sample was taken from the animals that had not had the ligature tied around the LAD. The samples were immediately pressed and frozen with clamps previously immersed for more than 10 min in liquid nitrogen. When clamping the sam ples, the tissue was pressed in such a way that the sub endo and subepicardial portions would be separated from the thin pressed frozen tissue (13) . The subendo cardial portion of the myocardium was collected and used for analysis. An ischemic myocardial sample was obtained from the subendocardial portion of the myo cardium, because the subendocardium is more sensitive to metabolic changes induced by ischemia (13) .
Biochemical analyses
The frozen samples of subendocardial tissue were pul verized in liquid nitrogen with a mortar and pestle. A part of the tissue powder was weighed and extracted with 6%%o perchloric acid. After centrifugation, the supernatant was neutralized and used to determine the levels of adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP), creatine phosphate (CrP), glucose-6-phosphate (G6P), fructose-6-phosphate (F6P), fructose l,6-diphosphate (FDP), pyruvate and lactate according to standard enzymatic procedures (14) . The remainder of the tissue powder was weighed and stood in an oven overnight to determine tissue wet weight and tissue water content. The contents of metabolites in the myocardium are expressed in g wet weight, because ischemia did not influence the water content of the myo cardium in the present experiment (data not shown).
The energy charge potential (ECP) was calculated from the concentration of ATP, ADP and AMP to estimate the myocardial energy state according to the equation
was calculated from the concentration of hexose phosphates to estimate the rate of glycolytic flux through the phosphofructokinase (PFK) reaction (16, 17) . The ratio of lactate to pyruvate was also calculated as an index of the cytoplasmic redox state of the myocardial cell.
Serum glucose was determined by the use of Reflolux II (Boehringer Mannheim-Yamanouchi, Co., Ltd., Tokyo), and serum insulin determined by a radioimmunoassay method (18) . To avoid some influences of blood sam pling, the venous blood was obtained 15 min before coro nary ligation and 5 min before termination of the experi ments.
Statistics
All values are expressed as a mean ±S.E. (n=number of preparations). Hemodynamic data and the levels of blood glucose and insulin were evaluated by a paired Student's t-test, and biochemical data were analyzed by one-way analysis of variance followed by the Dunnett's t-test. A value of P G 0.05 was considered statistically sig nificant.
RESULTS

Blood glucose and insulin
Serum glucose and insulin levels are shown in Fig. 1 . Serum levels of glucose and insulin were not changed by vehicle injection. Glibenclamide at either 0.3 or 3 mg/kg decreased blood glucose level significantly, whereas it in creased insulin level significantly. The increased level of insulin tended to decrease 70 min after glibenclamide in jection. Hemodynamics (Table 1) Systolic and diastolic blood pressures increased 30 and 60 min after glibenclamide administration.
Changes in the blood pressures were statistically significant in the glibenclamide 0.3 mg/kg-treated ischemic and 3 mg/kg treated nonischemic and ischemic groups. Heart rate sig nificantly decreased 30 min after the injection, except for the 0.3 mg/kg glibenclamide-treated nonischemic group. Coronary flow did not change after glibenclamide injec tion, Injection of vehicle did not modify the systolic blood pressure, heart rate and coronary flow appreciably. The diastolic pressure, however, increased slightly but significantly after vehicle injection. Ligation of the LAD, to stop the coronary flow through this artery, slightly decreased the blood pressures. A slight increase in heart rate was observed after coronary ligation in the vehicle treated animals, but not in the glibenclamide-treated ones. Double products (systolic blood pressure x heart rate) were not significantly changed by either gliben clamide injection or LAD ligation.
Energy metabolism (Figs. 2 and 3) In the vehicle-treated heart, the level of ATP significant ly decreased 3 min after ischemia and was even more decreased at 15 min after ischemia. The levels of ADP and AMP increased significantly 3 min after ischemia, and they returned to the nonischemic level 15 min after ischemia. Glibenclamide at either dose did not modify the ATP level in the nonischemic myocardium. The levels of ADP and AMP were significantly decreased by 0.3 mg/kg glibenclamide, but not 3 mg/kg. Decreases in the levels of ATP caused by ischemia were significantly enhanced by pretreatment with glibenclamide at a dose of 3 mg/kg. The ADP and AMP levels in the 3-min post ischemic myo cardium were increased, but the effects of glibenclamide did not reach significance as compared with those in the vehicle-treated hearts. ECP calculated from the adenine nucleotide levels was decreased significantly by ischemia in the vehicle and glibenclamide-treated heart. The ECP in 0.3 mg/kg of glibenclamide-treated nonischemic group was significantly higher as compared with that in the vehi cle-treated group, because of the low levels of ADP and Ischemia decreased similarly the creatine phosphate level significantly in both vehicle and glibenclamide-treated hearts (Fig. 3) . Again, the decrease in creatine phosphate level due to ischemia tended to be enhanced by gliben clamide, but no significant difference was observed.
Carbohydrate metabolism (Figs. 4 and 5)
In the vehicle-treated myocardium, ischemia significant ly increased the levels of G6P and F6P, while it significant ly decreased the level of FDP. Therefore the ratio of
was significantly increased by ischemia, indicating a negative crossover point between F6P and FDP. Pretreatment with glibenclamide at either dose enhanced significantly the increase in G6P level due to 15 min of ischemia, whereas it attenuated the decrease in the FDP level. The increase in the ratio of
caused by 15 min of ischemia ap peared to be potentiated by glibenclamide. Because the FDP level in the glibenclamide-treated 3-min post ischemic heart was high, the ratio was not changed by gliben clamide.
The level of lactate increased significantly after ische mia, depending on the period of ischemia. Because the level of pyruvate was not altered appreciably, the ratio of ratio caused by ischemia was also potentiated by 3 mg/kg of glibenclamide, and the difference in the ratio between the nonischemic group and the 3-min ischemic group was significant. 
DISCUSSION
The present study was undertaken to verify the hypothe sis that KATP channels play an important role in protect ing the myocardium against ischemic insults. Cole et al. (9) showed in guinea pig heart that recovery of cardiac function after ischemia and reperfusion is enhanced by a KATP channel opener and worsened by a KATP channel blocker. Mitani et al. (19) also reported in isolated per fused rat heart that nicorandil delays the onset of ische mia-induced contracture and glibenclamide accelerates it. Recently, Auchampach et al. (20) have reported that glibenclamide resulted in a worsening of the segment shortening function after reperfusion following ischemia. They suggest that KATP channels serve an endogenous function, which is to provide protection from ischemic insults (20) . In the present study, the decreased level of ATP and increased level of lactate induced by either 3 or 15 min of ischemia were significantly enhanced by gliben clamide. Similarly, the hexose monophosphate levels (G6P and F6P) increased during ischemia, and gliben clamide enhanced significantly their increases caused by 15 min of ischemia. This finding shows that glibenclamide worsens myocardial metabolic derangement during ische mia. This means that KATP channels were opened by ische mia, and the blockade of the opening by glibenclamide can worsen the metabolic derangement produced by ische mia. Auchampach et al. (20) have demonstrated that aprikalin, a potassium channel opener, improves segment shortening in the ischemic/reperfused myocardium only when given before the coronary occlusion, but not when given immediately before reperfusion. The opening of the KATP channels during ischemic period but not during reperfusion period is necessary for protecting the myo cardium from ischemic injury.
There is a discrepancy in the concentration of ATP at which KATP channels open between in vitro and in vivo experiments. According to the in vitro experiments, the KATP channel will open when the concentration of ATP is under a pM concentration (1) . Although the level of ATP decreases during ischemia, the level in the ischemic myo cardium is still at a mM concentration.
Nichols and Lederer (21) have demonstrated that the ATP/ADP ra tio, even within their physiological concentration rages, may influence cellular function in the heart via a direct action on the KATP channel. Compartmentalization of ATP in the cell (22) (23) have demonstrated that a guanosine triphosphate dependent protein (G protein), especially G;, reduces the channel sensitivity to ATP in cultured neonatal rat heart cells. Ischemia stimulates the release of adenosine from the myocardium (24) . It is possible to consider that the re leased adenosine activates the G protein through adeno sine receptors. Reduction of KATP channel sensitivity to ATP due to activation of G protein may open the chan nels although the concentration of ATP is still high.
Ischemia inhibits the glycolytic pathway at the level of PFK (25, 26) . In the present study, a negative crossover point between F6P and FDP was observed in the ischemic myocardium, suggesting an inhibition of glycolytic flux through the PFK reaction (Fig. 4) . In the ischemic myo cardium where there is no coronary flow, glycolysis may be inhibited to prevent an abnormal accumulation of the deleterious metabolic end products such as lactate and hydrogen ions (27) . Without a direct measurement of glycolytic flux, static measurements of the substrates and products of a reaction do not quantify the rate of glyco lytic flux (28) . Opie has stated clearly in his paper that measurement of glycolytic flux in regionally ischemic myocardium is not easy (26) . Aside these limitations, the ratio of ([G6P] + [F6P])/[FDP] is useful for estimating the metabolic deterioration in the ischemic myocardium. We have demonstrated that many cardioprotective drugs attenuate the increase in the ratio caused by ischemia (16, 29, 30) . The levels of myocardial lactate and pyruvate. Symbols are the same as those in Fig. 2 Glibenclamide at a high dose produces a significant increase in blood pressure and a decrease in heart rate ( Table 1) . Blockade of KATP channel opening may constrict systemic vascular smooth muscle (31) , and then increases peripheral vascular resistance. However, the coronary flow was not modified by glibenclamide in spite of its vasoconstrictive action. Imamura et al. (32) reported that intracoronary infusion of glibenclamide decreases coro nary blood flow without any change in mean aortic pres sure. In the present study, the coronary blood flow was probably maintained by elevation of the aortic pressure that increased perfusion pressure to propel the coronary flow. The decrease in heart rate may be due to a compen satory response to the hypertension. The elevation of the arterial blood pressures may be involved partly in the mechanism by which glibenclamide make the metabolic derangement worse because of increasing energy require ment of the heart. Double products did not change sig nificantly, however. Auchampach et al. (20) reported that a low dose of glibenclamide (1 mg/kg) results in sig nificant worsening of segment shortening during reperfu sion without systemic hemodynamic changes. Gliben clamide at 0.3 mg/kg in the present study also showed some enhancements of ischemic metabolic derangements under the less hemodynamic changes. Another possibility by which glibenclamide enhanced the myocardial meta bolic derangements during ischemia is via alterations in blood glucose and/or insulin levels. The lower dose of glibenclamide (0.3 mg/kg) also decreased the blood glu cose level and increased insulin level to the same extent as the higher dose of glibenclamide (3 mg/kg) did (Fig. 1) . To avoid the hypoglycemic effect of the drug, glucose solu tion was infused in our preliminary experiments. The infu sion of glucose, however, increased the insulin level fur ther (data not shown). It is very difficult to cancel both the effects of low glucose and high insulin levels on the ische mic myocardium. Schaffer et al. (33) 
